CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...
We expect CRISPR Therapeutics CRSP to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter. The ...
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results